Medytox said Thursday it has received marketing approval from the Ministry of Food and Drug Safety (MFDS) for Nuviju, the world’s first cholic acid–based fat-dissolving injection.

The product is indicated for the treatment of moderate to severe submental fat, commonly known as double chin.

Nuviju marks Medytox’s first chemical new drug and represents a significant breakthrough in the injectable fat reduction field.

Unlike conventional deoxycholic acid (DCA) injections, which are the global standard, Nuviju is formulated with cholic acid (CA) as the active ingredient.

The company emphasized that the new product was optimized to match the human body’s physiological acidity (pH), enhancing the fat-cell destruction effect while reducing pain, swelling, and bruising that frequently occur with existing treatments.

Medytox began its first clinical trial of Nuviju in 2018 and successfully completed the regulatory process after seven years of development. The company believes the differentiated safety and efficacy profile of the cholic acid formulation will position Nuviju as a game changer in the fat-dissolving injection market, which has been dominated by DCA products.

“The approval of Nuviju is a major achievement that demonstrates Medytox’s differentiated technology and research capabilities,” Medytox CEO Jung Hyun-ho said. “Building on our accumulated expertise in botulinum toxin and dermal filler development, we will maximize synergies across our aesthetic portfolio and pursue both domestic launch and global market expansion.”